Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Oct 2017
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Agitation; Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 13 Oct 2017 Status changed from recruiting to discontinued.
- 25 Jun 2014 New trial record